Meeting
2024 ASCO Annual Meeting
First-line treatment of follicular lymphoma (FL) with golcadamide, rituximab +/- nivolumab: An umbrella randomised phase 2 investigator-led study.
Authors
Geoffrey Chong
Grampians Health, Ballarat, Australia
Geoffrey Chong , Jodie Palmer , Allison Barraclough , Leonid Churilov , Colm Keane , Sze Ting Lee , Denise Lee , Sumita Ratnasingam , Charmaine Smith , Eliza Anne Hawkes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05788081
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr TPS7092)
DOI
10.1200/JCO.2024.42.16_suppl.TPS7092
Abstract #
TPS7092
Poster Bd #
70b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
First-line (1L) treatment of follicular lymphoma (FL) with atezolizumab and obinutuzumab (A+O) +/- radiotherapy (RT): Results from the FLUORO study.
First Author: Geoffrey Chong
Poster
2024 ASCO Breakthrough
Surufatinib plus toripalimab in advanced soft tissue sarcoma (STS): Results from a multicenter, single-arm, basket study.
First Author: Ying Cheng
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2024 ASCO Annual Meeting
Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
First Author: Umberto Vitolo